TY - JOUR
T1 - Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent pancreatic cancer
T2 - comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT.
AU - Kitajima, Kazuhiro
AU - Murakami, Koji
AU - Yamasaki, Erena
AU - Kaji, Yasushi
AU - Shimoda, Mitsugi
AU - Kubota, Keiichi
AU - Suganuma, Narufumi
AU - Sugimura, Kazuro
PY - 2010/8
Y1 - 2010/8
N2 - PURPOSE: The purpose of this study is to evaluate the accuracy of 2-deoxy-2-[F-18]fluoro-D: -glucose-positron emission tomography (FDG-PET)/computed tomography (CT) with intravenous contrast for depiction of recurrent pancreatic cancer, compared with PET/non-enhanced CT and CT. PROCEDURE: Forty-five patients previously treated for pancreatic cancer underwent PET/CT for suspected recurrence. Lesion status was determined on the basis of histopathology and radiological imaging follow-up. RESULTS: Patient-based analysis showed that sensitivity, specificity, and accuracy of PET/contrast-enhanced CT were 91.7%, 95.2%, and 93.3%, respectively, whereas those of PET/non-enhanced CT were 83.3%, 90.5%, and 86.7%, respectively, and those of enhanced CT were 66.7%, 85.7%, and 75.6%, respectively. In 21 patients whom the final diagnosis was obtained from the histopathologic examination, those figures of PET/contrast-enhanced CT were 94.7%, 50.0%, and 90.4%, respectively. The sensitivity of PET/contrast-enhanced CT in detecting local recurrence, abdominal lymph node metastasis, and peritoneal dissemination were 83.3%, 87.5%, and 83.3%, respectively. CONCLUSION: PET/contrast-enhanced CT is an accurate modality for assessing recurrence of pancreatic cancer.
AB - PURPOSE: The purpose of this study is to evaluate the accuracy of 2-deoxy-2-[F-18]fluoro-D: -glucose-positron emission tomography (FDG-PET)/computed tomography (CT) with intravenous contrast for depiction of recurrent pancreatic cancer, compared with PET/non-enhanced CT and CT. PROCEDURE: Forty-five patients previously treated for pancreatic cancer underwent PET/CT for suspected recurrence. Lesion status was determined on the basis of histopathology and radiological imaging follow-up. RESULTS: Patient-based analysis showed that sensitivity, specificity, and accuracy of PET/contrast-enhanced CT were 91.7%, 95.2%, and 93.3%, respectively, whereas those of PET/non-enhanced CT were 83.3%, 90.5%, and 86.7%, respectively, and those of enhanced CT were 66.7%, 85.7%, and 75.6%, respectively. In 21 patients whom the final diagnosis was obtained from the histopathologic examination, those figures of PET/contrast-enhanced CT were 94.7%, 50.0%, and 90.4%, respectively. The sensitivity of PET/contrast-enhanced CT in detecting local recurrence, abdominal lymph node metastasis, and peritoneal dissemination were 83.3%, 87.5%, and 83.3%, respectively. CONCLUSION: PET/contrast-enhanced CT is an accurate modality for assessing recurrence of pancreatic cancer.
UR - http://www.scopus.com/inward/record.url?scp=78049330730&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78049330730&partnerID=8YFLogxK
U2 - 10.1007/s11307-009-0271-7
DO - 10.1007/s11307-009-0271-7
M3 - Article
C2 - 19949988
AN - SCOPUS:78049330730
SN - 1536-1632
VL - 12
SP - 452
EP - 459
JO - Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
JF - Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
IS - 4
ER -
